Christian M. Matter
Christian M. Matter has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Amedeo Caflisch
University of Zürich
3 shared publications - Cristina Nevado
Department of Chemistry, University of Zürich, Zürich, Switzerland
1 shared publication Eleen Laul
Department of Chemistry, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland
1 shared publicationElena Bochenkova
Department of Biochemistry
1 shared publicationFiona Stamm
Department of Biochemistry
1 shared publication- Ivan Corbeski
University of Zürich
1 shared publication
Latest Publications
- Open Access
- 10 June 2026
- Published by American Chemical Society (ACS) in JACS Au
- Vol. 6 (7) , 3816-3827
Balancing Stability and Payload Release in Glutathione-Responsive PROTAC Prodrugs Targeting Prostate Cancer
- 10 June 2026
- Published by American Chemical Society (ACS) in JACS Au
- Vol. 6 (7) , 3816-3827
Open AccessBalancing Stability and Payload Release in Glutathione-Responsive PROTAC Prodrugs Targeting Prostate Cancer
- Open Access
- 10 March 2026
- Published by American Chemical Society (ACS) in ACS Bio & Med Chem Au
- Vol. 6 (2) , 130-144
Ligand-Induced Opening of a Cryptic Pocket in METTL14
The complex of methyltransferase-like proteins 3 and 14 (METTL3–14) is the main human enzyme that deposits the most abundant internal mRNA modification, N6-methyladenosine (m6A). In the heterodimeric complex, METTL3 acts as a catalytic subunit while METTL14 is involved in mRNA binding and complex stabilization. Here, we present the discovery of small-molecule ligands that bind to a cryptic pocket in METTL14 by protein crystallography. A comparative analysis of crystal structures revealed that the METTL14 cryptic pocket is closed in the apo structure of METTL3–14, and in the structures of METTL3–14 in the complex with the cosubstrate S-adenosyl-methionine (SAM) and a large number of SAM-competitive inhibitors. We first discovered compounds 1 and 2 that bind to both the SAM pocket in METTL3 and the cryptic pocket in METTL14. With this structural information, we designed compound 3 that binds only to the METTL14 cryptic pocket. Compound 3 does not inhibit the catalytic activity of METTL3–14 but can be used as an anchor for heterobifunctional molecules. We propose a route for its further development into heterobifunctional ligands, e.g., proteolysis targeting chimeras (PROTACs).
- 10 March 2026
- Published by American Chemical Society (ACS) in ACS Bio & Med Chem Au
- Vol. 6 (2) , 130-144
Open AccessLigand-Induced Opening of a Cryptic Pocket in METTL14
The complex of methyltransferase-like proteins 3 and 14 (METTL3–14) is the main human enzyme that deposits the most abundant internal mRNA modification, N6-methyladenosine (m6A). In the heterodimeric complex, METTL3 acts as a catalytic subunit while METTL14 is involved in mRNA binding and complex stabilization. Here, we present the discovery of small-molecule ligands that bind to a cryptic pocket in METTL14 by protein crystallography. A comparative analysis of crystal structures revealed that the METTL14 cryptic pocket is closed in the apo structure of METTL3–14, and in the structures of METTL3–14 in the complex with the cosubstrate S-adenosyl-methionine (SAM) and a large number of SAM-competitive inhibitors. We first discovered compounds 1 and 2 that bind to both the SAM pocket in METTL3 and the cryptic pocket in METTL14. With this structural information, we designed compound 3 that binds only to the METTL14 cryptic pocket. Compound 3 does not inhibit the catalytic activity of METTL3–14 but can be used as an anchor for heterobifunctional molecules. We propose a route for its further development into heterobifunctional ligands, e.g., proteolysis targeting chimeras (PROTACs).
- Open Access
- 20 January 2026
- Published by American Chemical Society (ACS) in ACS Bio & Med Chem Au
- Vol. 6 (2) , 160-167
Fine-Tuning a Transformer Model for METTL3 Lead Optimization
Transformers are machine learning models originally developed to translate between natural languages. Recently, a transformer model was trained on knowledge of medicinal chemistry, i.e., matched molecular pairs of nearly a million bioactive compounds from the ChEMBL database. Here, we customize (i.e., fine-tune) the pretrained model to enhance the affinity and/or metabolic stability of a series of inhibitors of methyltransferase-like protein 3 (METTL3). We first fine-tune the transformer model using a data set of about 500 METTL3 inhibitors with known binding affinities and validate it by retrospective analysis. Then, we fine-tune the original transformer model to simultaneously optimize binding affinity and metabolic stability in a prospective application. Two of the five METTL3 inhibitors predicted by the multiobjective optimized model show low-nanomolar potency and higher stability than the lead compound of the chemical series used for fine-tuning.
- 20 January 2026
- Published by American Chemical Society (ACS) in ACS Bio & Med Chem Au
- Vol. 6 (2) , 160-167
Open AccessFine-Tuning a Transformer Model for METTL3 Lead Optimization
Transformers are machine learning models originally developed to translate between natural languages. Recently, a transformer model was trained on knowledge of medicinal chemistry, i.e., matched molecular pairs of nearly a million bioactive compounds from the ChEMBL database. Here, we customize (i.e., fine-tune) the pretrained model to enhance the affinity and/or metabolic stability of a series of inhibitors of methyltransferase-like protein 3 (METTL3). We first fine-tune the transformer model using a data set of about 500 METTL3 inhibitors with known binding affinities and validate it by retrospective analysis. Then, we fine-tune the original transformer model to simultaneously optimize binding affinity and metabolic stability in a prospective application. Two of the five METTL3 inhibitors predicted by the multiobjective optimized model show low-nanomolar potency and higher stability than the lead compound of the chemical series used for fine-tuning.